Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotypes 2a and 2b and high viral load

Dig Dis. 2013;31(5-6):426-33. doi: 10.1159/000355381. Epub 2013 Nov 21.

Abstract

Objective: We investigated the impact of host genetics represented by the single nucleotide polymorphism (SNP) of the IL28B gene and viral genetic variations within the nonstructural protein 5A (NS5A) [including the interferon (IFN)/ribavirin (RBV) resistance-determining region (IRRDR) and the IFN sensitivity-determining region (ISDR)] on the outcome of pegylated IFN and RBV (PEG-IFN/RBV) treatment.

Methods: Sixty-six patients infected with hepatitis C virus (HCV)-2a or HCV-2b who received PEG-IFN/RBV for 24 weeks were examined.

Results: In HCV-2a, the major genotype of IL28B SNP showed a tendency toward association with sustained virological response (SVR) and rapid virological response (RVR), and four or more mutations in IRRDR (IRRDR[2a] ≥4) and one or more mutations in ISDR plus its carboxyl-flanking region (ISDR/+C[2a] ≥1) were significantly associated with SVR and RVR. In HCV-2b, one or more mutations in the N-terminal part of IRRDR (IRRDR/N[2b] ≥1) were significantly associated with RVR. Multivariate analysis identified the major genotype of IL28B SNP and IRRDR[2a] ≥4 as independent predictive factors of SVR in HCV-2a, with IRRDR[2a] ≥4 being more powerful than the IL28B SNP. Also, IRRDR[2a] ≥4 in HCV-2a and IRRDR/N[2b] ≥1 in HCV-2b were significant determiners of RVR.

Conclusion: The NS5A sequence heterogeneity and IL28B SNP are useful factors to predict the sensitivity to PEG-IFN/RBV therapy in HCV-2a and HCV-2b infections.

Publication types

  • Clinical Trial

MeSH terms

  • Amino Acid Sequence
  • Base Sequence
  • Demography
  • Drug Therapy, Combination
  • Female
  • Hepacivirus / drug effects*
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / genetics*
  • Hepatitis C, Chronic / virology
  • Humans
  • Interferons / chemistry
  • Interferons / pharmacology
  • Interferons / therapeutic use*
  • Interleukins / metabolism
  • Kinetics
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Polyethylene Glycols / chemistry
  • Ribavirin / pharmacology*
  • Ribavirin / therapeutic use*
  • Risk Factors
  • Sequence Analysis, DNA
  • Treatment Outcome
  • Viral Load / genetics*
  • Viral Nonstructural Proteins / chemistry
  • Viral Nonstructural Proteins / genetics

Substances

  • interferon-lambda, human
  • Interleukins
  • Viral Nonstructural Proteins
  • Polyethylene Glycols
  • Ribavirin
  • Interferons
  • NS-5 protein, hepatitis C virus